Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024
Reports Net Revenues of $171.8 Million for the Three Months Ended March 31, 2024 RANCHO CUCAMONGA, CA / ACCESSWIRE /...
Clinical Trial
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024
Reports Net Revenues of $171.8 Million for the Three Months Ended March 31, 2024 RANCHO CUCAMONGA, CA / ACCESSWIRE /...
Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
Click here to register for May 14 investor webcastCompany plans to file its Earnings Report on May 14, 2024 on...
Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
Click here to register for May 14 investor webcastCompany plans to file its Earnings Report on May 14, 2024 on...
Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update
Heavily pre-treated breast cancer patient who achieved stable disease on study, remains on treatment for more than eleven months after...
Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update
Heavily pre-treated breast cancer patient who achieved stable disease on study, remains on treatment for more than eleven months after...
Yunu Delivers a New Imaging Workflow Paradigm for Investigator-Initiated Trials
Investigators rapidly activate sites, expand trial reach, and achieve real-time data oversight with a complete and affordable cloud-based research imaging...
A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox
NV-387 Possesses Strong Orthopoxvirus Activity Relevant to Both Sexual and Inhalation Modes of Transmission, Says NanoViricides SHELTON, CT / ACCESSWIRE...
Genflow Biosciences PLC Announces Restoration of Listing
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET...
Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update
Entered into a worldwide license and collaboration agreement for rusfertide with Takeda; Cash runway extended through Q4 2027 Enrollment in...
Science 37 Wins 2024 MedTech Breakthrough Award for “Clinical Efficiency Innovation”
Science 37’s Patient Recruitment Recognized in Prestigious International Annual Awards Program for Standout Digital Health & Medical Technology Products and...
MedTech Breakthrough Announces Medidata as Winner of the “Clinical Trial Innovation Award” in 8th Annual MedTech Breakthrough Awards Program
Prestigious International Program Recognizes Standout Digital Health & Medical Technology Products and CompaniesLOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) --...
Standout Digital Health and Medical Technology Innovators Honored in 2024 MedTech Breakthrough Awards Program
International Annual Awards Program Recognizes Outstanding Health & Medical Technology Products and CompaniesLOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) --...
Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
-Preclinical findings show exosome-based therapeutic approach for the treatment of arginase-1 deficiency (ARG1-D)- -Presentation to be featured in an oral...
Curia and Carterra Partner on Biologics Symposium to Further Biotechnology Research in the Pacific Northwest
Curia & Carterra Biologics Symposium Biologics symposium slated for May 31 in Seattle, WA ALBANY, N.Y. and SALT LAKE CITY,...
NeuroSigma Announces Acceptance into 2024 Cohort of the KidsX Accelerator Program
LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. today announced its acceptance into the 2024 cohort of the...
AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast
OCALA, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that...
Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting
In preclinical models of cornea endothelial dystrophies, a Surrozen antibody-based Wnt mimetic reduced corneal edema and stimulated endothelial cell proliferation...
Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update
-- Recruitment of the commercial team for our infertility portfolio and the pivotal trial of FemBloc® for permanent non-surgical birth...
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
Pre-treatment Sample of Patient’s Blood Showed Rapid and Potent Depletion of CD19+ B Cells in Ex Vivo Cytotoxicity Assay with...